Imricor Advances US Expansion as NorthStar Opens Hospital Growth Opportunities

Highlights

• First US customer establishes a foothold, with more hospital purchases potentially approaching.
• Broader FDA clearances expand access, while ablation approval awaits another milestone.
• Fresh capital supports commercial expansion, but revenue growth must follow.

Quarterly Update Sets Out US Opportunity

Imricor Medical Systems, Inc. (ASX: IMR) announced its second-quarter 2026 results on 10 August 2026, detailing its entry into the US market and progress across its regulatory programme. The update covered the quarter ended 30 June, alongside subsequent commercial developments.

The company develops technology that enables cardiac procedures inside magnetic resonance imaging scanners. Its approach avoids ionising radiation while allowing clinicians to visualise soft tissue and guide instruments during treatment.

First Hospital Customer Establishes Commercial Foothold

After quarter-end, Imricor announced that Rady Children’s Hospital–San Diego would become its first US customer, purchasing NorthStar for a radiation-free cardiac catheterisation programme.

Several additional hospitals were nearing purchasing decisions at the announcement date. Management expected initial NorthStar sales revenue to surpass the European business’s total revenue for 2025, highlighting the potential significance of securing early installations.

Regulatory Progress Supports Broader Adoption

During the quarter, the US Food and Drug Administration broadened the permitted use of NorthStar and the Vision-MR Diagnostic Catheter to include every age group. Separately, Imricor submitted the third module of its premarket approval application for the Vision-MR Ablation Catheter. The final module will follow completion of the VISABL-AFL clinical trial, which was approaching its remaining patient enrolments.

Existing clearances support commercial deployment, while the ablation opportunity remains dependent on further clinical and regulatory progress.

Financial Results Highlight the Scaling Challenge

Quarterly revenue fell 6% to US$60,500, with devices used in clinical trials generating no recognised revenue. Net loss narrowed to approximately US$7.4 million.

Operating cash outflow declined to US$6.1 million, compared to US$7.9 million in the preceding quarter. A completed A$60 million placement strengthened funding, while cash and short-term investments totalled US$67.5 million at 30 June.

Outlook: Hospital Adoption Becomes the Next Test

Imricor’s next phase centres on converting hospital interest into installations and sustained procedure volumes. Funding supports that effort, but commercial execution and completion of outstanding approval requirements will determine how quickly the opportunity translates into revenue.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au